Becton, Dickinson (BDX) Gets USFDA Clearance For BD MAX

Leading global medical technology company, Becton, Dickinson and Company BDX recently announced that it got the clearance for its proprietary BD MAX CT/GC/TV assay from the U.S. Food and Drug Administration (FDA).
The BD MAX CT/GC/TV assay provides health care providers the ability to detect for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas Vaginalis (TV) from a single specimen through just one test. Notably, CT, GC and TV are among the most prevalent sexually transmitted infections (STIs). Per the U.S. Centers for Disease Control and Prevention (CDC) estimate, about 2.86 million new chlamydial infections and 820,000 gonorrheal infections occur each year.

BD MAX system is a fully integrated, automated molecular platform, which can run both In Vitro Diagnostics (IVD) and open system assays in a flexible and efficient manner. Specimen collection options are also flexible. It can use urine specimens, self-collected vaginal swabs and clinician-collected endocervical swabs. Once samples are loaded onto the BD MAX System, results will be ready in less than three hours. Lastly, all the reagents are ready-to-use and can be stored at room temperature.

BD’s innovative product pipeline is a key growth driver. A vast array of regulatory approvals both in the U.S. and international markets are helping the company to rapidly expand its product portfolio. Moreover, the collaboration with Check-Points will drive demand for BD MAX assays that detect carbapenem-resistant organisms (CRO) in international markets. Both companies also plan to develop and commercialize a next-generation CRO assay for launch outside the U.S. in 2017 and later in the U.S.

Further, the partnership with Central Admixture Pharmacy Services (“CAPS”) will allow BD Intelliport Medication Management System customers to buy a portfolio of frequently used CAPS' pre-filled anesthesia syringes.

We believe that these partnerships and collaborations will lend BD a competitive edge, which will eventually boost its overall results. Although the Zacks Consensus Estimate for full-year 2016 has remained steady at $8.56 over the last seven days, it reflects year-over-year growth of almost 19.6%.

Zacks Rank & Key Picks
Currently, BD carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical sector are Almost Family Inc. AFAM, RadNet, Inc. RDNT and US Physical Therapy Inc. USPH. Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
RADNET INC (RDNT): Free Stock Analysis Report
US PHYSICAL THR (USPH): Free Stock Analysis Report
ALMOST FAMILY (AFAM): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

Comments on RDNT stock